Emily and Joey Spadafore watched helplessly as their 3-month-old son, Benjamin, battled RSV for a week in the hospital.

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

What should you know about RSV and who can get it? In many cases, there is a difference for adults and children, ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk ...

The respiratory syncytial virus (RSV) vaccine triggered strong immune responses among people aged 60 years and older during ...

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for active immunization for the prevention of ...

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Expectant mums and elderly people who haven’t yet had their vaccination against the life-threatening RSV virus that is spreading in London ...